Thymosin Alpha-1 vs TB-500: Research Peptide Comparison

Mechanisms: Immune Modulation vs Actin Sequestration

Both thymosin alpha-1 (sequenced 1977) and thymosin beta-4 (sequenced 1981) were isolated from calf-thymus 'thymosin fraction 5' by Goldstein's group; they share a naming family, not a gene or function. Thymosin alpha-1 and thymosin beta-4 are encoded by separate genes, have no sequence homology, and perform entirely different cellular functions. Thymosin alpha-1 is a T-cell maturation factor; thymosin beta-4 is a cytoskeletal regulator. The shared name reflects historical discovery context—not functional relationship.

Thymosin Alpha-1: T-Cell Differentiation and Immune Modulation

Thymosin alpha-1 (Tα1) is the N-terminal 28-amino-acid fragment of prothymosin alpha, an acidic nuclear protein encoded by the PTMA gene. The peptide was characterized as a T-cell maturation factor in the 1970s and 1980s.

Mechanism: Thymosin alpha-1 modulates T-cell differentiation, enhances Th1 cytokine production (IL-2, IFN-γ), and influences dendritic cell maturation and antigen presentation. Tα1 has been reported to activate dendritic cells through Toll-like receptor signaling (Romani et al., Blood 2004, PMID 14982877). The peptide has been studied in models of viral infection (hepatitis B, hepatitis C, HIV), sepsis, and as an adjuvant in cancer immunotherapy.

Published clinical data: Thymalfasin (synthetic Tα1, marketed as Zadaxin by SciClone Pharmaceuticals) has been evaluated in multiple clinical trials. SciClone reports thymalfasin (Zadaxin) is approved in over 30 countries; indications vary by country and include chronic hepatitis B, hepatitis C, use as a vaccine adjuvant, and certain cancers. Documented approvals include China, India, the Philippines, Argentina, Mexico, Peru and Venezuela. Thymosin alpha-1 is not FDA-approved in the United States.

Research-grade availability: Synthetic thymosin alpha-1 is available through research peptide suppliers. Quality documentation should confirm the 28-amino-acid sequence with N-terminal acetylation, verified by mass spectrometry. Laboratories should request batch-specific COAs confirming identity, purity (≥95% by HPLC), and endotoxin levels for cell culture or animal studies.

TB-500 / Thymosin Beta-4: Actin Sequestration and Cell Migration

Thymosin beta-4 (Tβ4) is a 43-amino-acid peptide encoded by the TMSB4X gene on the X chromosome. It is one of the most abundant intracellular peptides in mammalian cells and functions as a G-actin-sequestering protein, regulating actin polymerization dynamics critical for cell motility, wound healing, and tissue repair.

Mechanism: Thymosin beta-4 binds monomeric (G-)actin in a 1:1 complex, preventing its incorporation into filamentous (F-)actin. This sequestration maintains a pool of unpolymerized actin available for rapid cytoskeletal remodeling during cell migration. Beyond actin binding, Tβ4 influences angiogenesis, collagen deposition, inflammation modulation, and stem cell migration in preclinical wound healing and cardiac repair models. Key studies by Huff, Safer, and colleagues in the 1980s–1990s defined the actin-sequestering mechanism (Safer et al., J Biol Chem 1991, PMID 1999398).

Clinical and preclinical data: Preclinical studies in rodent models have demonstrated accelerated wound healing, improved cardiac function post-myocardial infarction, and enhanced tendon repair. Small early-phase clinical trials of Tβ4 have been reported in dermal-wound and ophthalmic settings; see Goldstein et al., Expert Opin Biol Ther 2012, PMID 22074294 for an overview.

TB-500 terminology: "TB-500" is a commercial designation used in the research peptide market. The term historically referred to synthetic peptides modeled after thymosin beta-4 or its active fragments. However, the exact sequence, length, and acetylation status of "TB-500" products vary by supplier. Some vendors sell full-length 43-amino-acid Tβ4; others sell shorter fragments or analogs. Laboratories must verify the molecular identity via COA, including mass spectrometry confirmation of sequence and molecular weight. Assuming "TB-500" equals native Tβ4 without COA verification is not advisable.

Regulatory Status and Published Evidence

Thymosin Alpha-1: Approved Outside U.S.; Not Covered by HHS Draft 503A Discretion

SciClone reports thymalfasin (Zadaxin) is approved in over 30 countries; indications vary by country and include chronic hepatitis B, hepatitis C, use as a vaccine adjuvant, and certain cancers. Documented approvals include China, India, the Philippines, Argentina, Mexico, Peru and Venezuela. It is not FDA-approved in the United States. Its clinical program has included large phase-3 trials with synthetic thymosin alpha 1 in several countries, including the United States, Italy, and China (Tuthill et al., Ann N Y Acad Sci 2010, PMID 20536460).

Thymosin alpha-1 is not one of the six peptides in HHS's draft Appendix A (filed October 28, published October 30, 2026); the interim 503A enforcement-discretion policy does not cover it. Appendix A lists exactly six peptides: BPC-157, epitalon, KPV, MOTS-c, semax, TB-500. For additional context, see the HHS peptide enforcement discretion analysis on PurePep Vital.

TB-500 / Thymosin Beta-4: Not Approved; WADA Prohibited; TB-500 Acetate on HHS Draft 503A

Thymosin beta-4 is not FDA-approved for any indication. Preclinical data in wound healing, cardiac repair, and ophthalmology models exist; human clinical trial data remains limited and exploratory. As noted above, small early-phase studies have been reported, but no large-scale efficacy trials have led to regulatory approval.

Thymosin beta-4 (and its derivatives, including TB-500) is classified as a prohibited substance by the World Anti-Doping Agency (WADA). It is listed under S2.3 Growth Factors and Growth Factor Modulators ('Thymosin-β4 and its derivatives e.g. TB-500'), class S2, prohibited at all times (in- and out-of-competition), non-Specified. This classification applies to all athletes subject to the WADA Code. Laboratories conducting research involving athletes or sports medicine contexts must comply with WADA regulations and institutional review board requirements.

TB-500 acetate — defined in Appendix B as Ac-LKKTETQ (7 amino acids, N-terminal acetyl, MW 949.1 g/mol), subcutaneous or intramuscular only — was included on HHS's draft Appendix A for interim enforcement discretion under section 503A, filed October 28 and published October 30, 2026. Full-length thymosin beta-4 is not the listed substance. This is not final 503A Bulks List inclusion and not FDA approval. The draft interim policy does not authorize RUO distribution outside compounding pharmacy contexts.

Confusion and Naming Clarity

Why the shared "thymosin" name causes confusion: Both thymosin alpha-1 (sequenced 1977) and thymosin beta-4 (sequenced 1981) were isolated from calf-thymus 'thymosin fraction 5' by Goldstein's group; they share a naming family, not a gene or function. Modern molecular biology reveals these peptides come from different genes, have no sequence homology, and serve completely different cellular roles.

Common misconceptions: Researchers sometimes assume "thymosins" are interchangeable or functionally related. They are not. Thymosin alpha-1 is an immune modulator; thymosin beta-4 is a cytoskeletal protein. Procurement and experimental design should never conflate the two. When sourcing research-grade materials, always verify gene origin, sequence, and molecular weight via COA—particularly for "TB-500," where catalog definitions vary.

Quality Documentation and COA Verification

For thymosin alpha-1: Verify the 28-amino-acid sequence (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH, where Ac denotes N-terminal acetylation). Molecular weight should be ~3,108 Da. Batch-specific COA should include HPLC purity (≥95%), mass spectrometry confirming the acetylated N-terminus, and endotoxin testing if intended for cell or animal work.

For TB-500 / thymosin beta-4: First, confirm what "TB-500" means from the supplier. If the product is full-length Tβ4, the sequence is 43 amino acids with molecular weight ~4,963 Da. If it is a fragment or analog, confirm the exact sequence and length. COA must include HPLC purity, mass spec identity confirmation, and endotoxin data. Do not assume "TB-500" equals native Tβ4 without documentation.

See how to read a peptide COA and COA authenticity verification for detailed quality-control guidance. Both thymosin alpha-1 and TB-500/Tβ4 require rigorous batch verification before use.

Comparison Summary for Laboratory Procurement

When to consider thymosin alpha-1: Research focused on T-cell differentiation, immune modulation, Th1/Th2 cytokine balance, viral infection models, or cancer immunotherapy adjuvants. Published human clinical trial data exists (thymalfasin in hepatitis and cancer). Appropriate when institutional procurement policies accept peptides with international regulatory approval but lacking FDA approval.

When to consider TB-500 / thymosin beta-4: Research requiring actin-sequestration models, cell migration assays, wound healing endpoints, or angiogenesis studies. Predominantly preclinical data; limited human trials. Appropriate when WADA prohibited status and sequence-definition ambiguity (for "TB-500" catalog terms) are addressed in compliance protocols and COA verification workflows.

Mechanistic orthogonality: Thymosin alpha-1 and TB-500/Tβ4 target completely different pathways—immune signaling vs cytoskeletal dynamics. We found no published study evaluating the combination (PubMed search, November 2026). Conservative approaches are advisable for multi-peptide protocols.